

Special Issue

10th Anniversary of Biomedicines—Novel Targets for Cranial Tumors

Message from the Guest Editors

Intracranial tumors may arise from the brain or other structures, such as the meninges, cranial nerves, and pituitary gland. The peculiarity of these tumors is that histologically benign neoplasms can also be life threatening, due to the non-expandability of the intracranial system. The treatment options for intracranial tumors have not significantly changed over the last 20 years; surgery (from biopsy to total resection) still represents the primary option for both benign and malign neoplasms, with the exception of some pituitary adenomas. Despite advances in technology and knowledge, prognosis has not dramatically changed either. The identification of novel potential targets for therapy and diagnosis is therefore strongly needed. This Special Issue aims to collect original papers demonstrating possible novel targets for diagnosing or treating intracranial tumors, including, but not limited to, gliomas, schwannomas, meningiomas, pituitary adenomas, and metastases.

- intracranial tumor
- pituitary adenoma
- biomarkers
- targeted therapy
- novel targets

Guest Editors

Prof. Dr. Pasquale De Bonis

Prof. Dr. Gianluigi Zona

Dr. Veronica Tisato

Prof. Dr. Tullio Florio

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117448

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).